Project Grant R41HL165958
Award Date
9/7/23
Completion Date
8/31/24
Dollars Obligated
$276K
Federal Agency
National Heart Lung and Blood Institute
Awardee
WR Biotech, LLC (HLVEXZFJKCF2)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
The National Heart Lung and Blood Institute (NHLBI) awarded a $989,908 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Board of Regents of Nevada System of Higher Education, doing business as the University of Nevada, Las Vegas (UNLV). The 4-year grant, effective January 1, 2025, aims to improve the efficacy of cell-based cardiac repair by examining whether treating mesenchymal stem cells (MSCs) with recombinant Wnt11 (Rwnt11) can enhance their ability to repair...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded Sigt LLC a $293,880 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of this Phase 1 SBIR grant is to develop a novel "Intraoperative Cardiac Pulsed Field Ablation Lesion Assessment System" (PFA-LAS) that can monitor procedure parameters and confirm durable lesion formation during cardiac pulsed electric field ablation procedures for atrial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $3,367,846 to Nour Heart Inc. over 24 months from September 2024 to June 2026. The project aims to develop and test the bioenergetic cardioprotective drug Nourexal (cyclocreatine phosphate, or CCRP) to increase the utilization of donor hearts for transplantation. Key activities include producing GMP-grade CCRP, conducting preclinical safety studies...